Don’t Miss TipRanks’ Half-Year Sale
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
Pacific Edge Limited ( (PFGTF) ) just unveiled an announcement.
Pacific Edge Limited has successfully raised NZ$16 million in a placement of new ordinary shares, exceeding its initial target by NZ$1 million due to strong shareholder support. The funds will be used to capitalize on recent clinical and commercial milestones, expand in non-Medicare channels, and work towards regaining Medicare coverage for its tests. The inclusion of Cxbladder in the American Urological Association’s guidelines is seen as a significant opportunity to build commercial momentum, despite the recent loss of Medicare coverage.
More about Pacific Edge Limited
Pacific Edge Limited is a global leader in cancer diagnostics, specializing in the development and commercialization of bladder cancer diagnostic and prognostic tests. The company is headquartered in Dunedin, New Zealand, and offers its Cxbladder suite of non-invasive genomic urine tests globally through its certified laboratories in New Zealand and the USA. These tests are designed for risk stratification of urothelial cancer, improving patient experience, and optimizing clinical workflows.
Find detailed analytics on PFGTF stock on TipRanks’ Stock Analysis page.